The efficacy of topical vaccines for prevention of acute respiratory infections in children with bronchial asthma
In an open comparative controlled study in two groups of children (n = 100) aged 3-11 years with bronchial asthma (BA) of varied severity, the efficacy of using a topical vaccine for prevention of acute respiratory infections (ARI) and associated exacerbations of BA was assessed. As was found, the use of the intranasal vaccine IRS® 19 in patients with BA promoted enhancement of the functional activity of T- and B-cell immunity, and the system of phagocytosis. Clinically, this was accompanied by a less number of ARI episodes a child had, their shorter duration, a decreased number of BA exacerbations, first of all, of those associated with intercurrent infections